SCHEMBL7792911

SCHEMBL7792911

NC(=O)CC(O)C(O)C(OCc1ccccc1)C(N)=O

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 4/20 0.51
SLC1A2 P43004 4/20 0.51
SLC1A1 P43005 4/20 0.51
MEN1 O00255 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
KMT2A Q03164 1/20 0.51
ABCB1 P08183 1/20 0.39
PARP10 Q53GL7 1/20 0.38
EPHX1 P07099 1/20 0.37
ALDH1A1 P00352 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HIF1A Q16665 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7977999 0.88 SLC1A3 (0.60) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL7347112 0.86 PARP10 (0.40) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL7789772 0.86 MAOB (0.40) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL7792922 0.84 MAOB (0.45) PARP10
SCHEMBL7792895 0.81 ALDH1A1 (0.47) SLC1A3SLC1A2SLC1A1PARP10ALDH1A1
SCHEMBL7784358 0.79 SLC1A3 (0.51) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL7967798 0.77 SLC1A1 (0.51) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL7789787 0.77 SLC1A1 (0.51) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL7350704 0.75 SLC1A2 (0.44) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL10439884 0.74 SLC1A2 (0.59) SLC1A3SLC1A2SLC1A1MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1118476-C Antiviral protease inhibitors MEDIVIR AB (SE) 2003-08-20 CN disclosed
US-20010044547-A1 Antiviral protease inhibitors MEDIVIR AB 2001-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010044547-A1 Antiviral protease inhibitors PEPD, PREP, CTSL SLC1A3 2604/4885SLC1A2 3813/4885SLC1A1 3086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.